Latest News
Texas Instruments Q2 Revenue Hits Record, Cash Conversion Surges
Texas Instruments (NASDAQ:TXN) reported record Q2 revenue of $5.46 billion, beating estimates and showing a surge in cash conversion to 95% of net income, excluding CHIPS Act grants.
Rani Therapeutics Soars 29%, Narrows Nasdaq Compliance Gap to 11%
Rani Therapeutics shares jumped 29.4% to $0.89, reducing the gap to Nasdaq's $1 minimum bid to about 11%. CEO Talat Imran's open-market purchase and promising Phase 1a results for RT-114 fueled the rally.
Huntington Bancshares Q2 Preview: Deal-Driven Growth Meets EPS Expectations
Huntington Bancshares (HBAN) closes up 0.6% ahead of Q2 earnings, with analysts eyeing deal-driven EPS growth amid integration costs and margin pressures.
Rigetti Computing's Strong Cash Position Offsets Steep Revenue Multiple
Rigetti Computing shares rose 7.7% since Friday, outperforming quantum peers, as its $569M cash reserve highlights a 290x sales multiple.
Tesla Q2 earnings miss on profit, beat on cash flow, shares dip
Tesla's Q2 adjusted earnings of $0.33 per share missed the $0.55 consensus, but free cash flow of -$1.09B was better than the expected -$3.25B. Shares slipped 2.6% in after-hours trading.
IBM Trims 2026 Revenue Forecast, Puts Pressure on H2 Cash Flow
IBM cut its 2026 revenue growth forecast to 4%-5% and held its cash flow target, raising the bar for H2. Q2 revenue of $17.16B fell short of analyst expectations.
Alphabet Cloud Drives Profit Surge as Free Cash Flow Turns Negative
Alphabet's cloud division powered 63% of operating profit growth, but free cash flow turned negative at -$5.9B due to soaring capital expenditures.
Zhibao Surges 57% on 3,500 Bitcoin PIPE Deal, Dilution Details Unclear
Zhibao Technology (ZBAO) shares surged 57% to $0.285 after a non-binding PIPE deal involving 3,500 bitcoin, valued at $230.2 million. Key details on pricing and dilution are still missing.
Advanced Biomed Surges 74.6% After Terminating $25M Equity Facility
Shares of Advanced Biomed (ADVB) jumped 74.6% after the company terminated a $25 million equity facility, removing overhang of potential dilution.
Knightscope Stock Jumps 46% on Q2 Preliminary Revenue Beat
Knightscope shares rose 46% to $2.09 after preliminary Q2 revenue of $9 million, more than three times last year's figure, though slightly below Q1 pro forma levels.